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INTRODUCTION
Sick euthyroid syndrome can be described as abnormal findings on
thyroid function tests that occur in the setting of a non thyroidal illness
(NTI) without preexisting hypothalamic-pituitary and thyroid gland
dysfunction.1-3
A decreased level of serum total triiodothyronine (T3) is the most
common thyroid function abnormality in patients with acute illness[4] and
can be detected within 2 hours after the onset of severe physical stress.[5]
As the severity of illness progresses, there is gradual development of a
more complex syndrome associated with low levels of T3 and thyroxine
(T4).[6,7]Levels of thyrotropin (TSH) remain unchanged or slightly reduced.
The conversion of the pro-hormone (Thyroxine, T4) to the active form is
reduced due to decreased 5’-deiodinase activity peripherally and production
of reverse T3 (rT3), the inactive metabolite, is increased.
These thyroid hormone changes may be mediated in part by cytokines
or other inflammatory mediators, acting at the level of the hypothalamus
and pituitary, the thyroid gland, and the hepatic deiodinase system, as well
as on binding of thyroxine to thyroid binding globulin.
It remains unresolved whether the hormone responses in the sick
euthyroid syndrome represent part of an adaptive response, which lowers
tissue energy requirements in the face of systemic illness, or a maladaptive
response, which induces damaging tissue hypothyroidism.
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Consequently, the use of thyroid hormone therapy in the sick euthyroid
syndrome is controversial.
Recovery from the underlying illness is accompanied by disappearance
of the thyroid abnormalities.
Altered thyroid hormone levels have been reported in starvation,acute
and chronic medical illnesses, bone marrow transplantation, surgery,trauma,
myocardial infarction 4 and, in fact, can be seen in any severe systemic
illness.
The more profound the changes in hormone pattern, the poorer the
prognosis.8.
Sick euthyroid syndrome has also been demonstrated in acute
organophosphate poisoning.(9)
The aim of the present investigation were to study the occurrence of
Sick Euthyroid syndrome in patients with acute pesticide poisoning 31-32
and to evaluate whether such sick euthyroid syndrome positivity have a
prognostic significance in the outcome of acute pesticide poisoning.
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REVIEW OF LITERATURE
HISTORY:
In the era of industrial revolution many organophosphorous compounds
were synthesized. Organophosphates(OPs)are chemical substances
originally produced by the reaction of alcohols and phosphoric acid.
As early as 1854, Clermont prepared tetra ethyl pyrophosphate(TEPP).
OPC made its mark in modern chemistry when Lange and Krueger recorded
the synthesis of di-methyl di-ethyl phosphor fluoridates in 1932(10). They
observed that inhalation of these compounds produced blurring of vision
and choking sensation.But OPC as pesticides were produced by a group
of German scientists led by Gerhard Schrader,Farben Febriken and bayer
1937.The possibilities of potential chemical warfare with these agents were
explored by Nazis in World War II.Indeed  Sarin(isoproyl methyl
phisphonosluoridate) was used by Iraq agaisnt Kurdish rebels in villages of
IRAQ (11).The residues of Sarin were still found in analysis of the soil.In
1944 Schrader synthesized parathion which was widely used as pesticide,
In 1870 Fraser developed atropine as an antidote to physostigmine.Collomp
in 1949 experimented atropine against mucarinic effects of nerve gas.
In 1995  Davies introduced oximes and I.B Wilson confirmed its usefulness
in acute OPC poisoning. Namba for the first studied GK-11 an anti
Glutamimetic drug as neuro protective agent in OPC in 1997 In 1998 adenosine
receptor antagonist role was studied in OPC  necessitating further studies.
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Historic and new uses of organophosphates:
The first organophosphate was synthesized in 1850.Physostigmine
was used to treat glaucoma in the 1870s.By the 1950s,synthetic cholinesterase
inhibitors were being used for skeletal muscle and autonomic disorders.Some
organophosphates were tried in the treatment of Parkinsonism.
In 1986,testing began for tacrine, the first cholinesterase inhibitor to
be tried for Alzheimer disease;it was released for clinical use in 1993.The
blood-brain barrier has been the limiting factor in developing a   Cholinestrase
inhibitor for use in dementia. A new drug, rivastigmine, is now available.
Reported adverse effects are nausea and vomiting,with resultant weight
loss because of the increase in cholinergic activity .It has been shown to be
useful in mild to moderately severe Alzheimer disease.
Recently, pyridostigmine has been tried for the fatigue of post polio
syndrome.Unfortunately, the study showed no benefit.
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TABKE1 : CLASSIFICATION AND THEIR STRUCTURE
Sl.No. Common Name Trade Name
1. Acephate Asataf,Orthene,Starthene
2. Chlorpyrifos Dursban,Durmet,Lorsban
3. Dichlorvas Noovan
4. Dimethoate Rogar,Tara909,Fosfamid
5. Fenitrothian Surmunion,Nitrophos
6. Fenthion Baycid,Baytex
7. Malathion Cythion,Chemathion
8. Methyl Parathion Metacid,Folitav,
9. Monocrotophos Monosron,Nuvacron,Luphos
10. Phorate Thimet,Pempart
11. Parathion Folidol,Ekatox
12. Phosphomidan Dimecron,Famfos
13. Quinalphos Ekalux
GENERAL CHEMICAL STRUCTURE
Organophosphorous compounds are bascially esters of phosphoric
acid or of phosphorothioc acids(12). The R denotes either ethyl or methyl
group.The organothiophosphates which contains double bonded sulphur
group are converted to organophosphates in the liver.Phosphonate
contains an alkyl(R-)in place of one alkoxy group(RO-). The X is called
the leaving  group and is the principal metabolite for species identification.(13).
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Table 2
Highly toxic:
Sl.no Brand name Chemical name
1 Dimecron Phosphomidan
2 Folidol Ethyl parathion
3 Celethion Chlorthiophos
4 Systox Demeton s methyl
5 Trithion Carbophenothion
6 Moonbug,metacid Methylparathion
7 Bloom Dichlorvas
RO
RO
S (or O)
X (Leaving Group)
P
Moderately toxic :
Sl.no Brand name Chemical name
1 Baytex Fenthion
2 Entex Formothion
3 Finit Malathion
4 Tic 20 Fenitrothion
5 Spectacide Diazinon
6 Canon,classic 20 Chlorpyriphos
7 Abate Temephos
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Others :
Sl.no Brand name Chemical name
1 Hydan,hinosan Edephenophos
2 Kinadon,siccomedon Ph osphenidone
3 Josh,Shikari Triazophos
4 Monocrown,monosul Monocrotophos
5 Rogor,Digor Dimethoate
6 Ekalux Quinalphos
7 Actellic pirimiphos
KINETICS:
The kinetics of each group are highly dependent upon many factors
such as route of administration such as ingestion,  inhalation, transdermal
and transmucosal exposure,distance from target organ ,local versus systemic
metabolisim and activation,route of elimination, endogenous hydrolysis and
consumption of the compound by non specific esterases. Each group has
its chemical structure, R-groups attached to the sulphur,carbon,or
phosphorus entity,tightness of the bond to the central atom and the inherent
affinty to cholinesterase .(14) After absorption the chemical are equally
distributed in all tissues but predominantly in liver and the renal.Lipophilic
compounds reach maximum concentration in neural and other lipid rich
tissues. Plasma half life after single dose administration depends upon the
type of opc and route of exposure and it may range from few minutes to
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few hours.Metabolism occurs mainly by three ways namely oxidation,
hydrolysis by esterases and transfer of portion of molecule to glutathione.
Urinary and faecal excretion occurs in 48 hours where in 80-90% of the
compund is eliminated (15).  Most of the agents show some symptoms and
signs within six to ten hours(16) with the exception of fat soluble compounds
where it may take several days to weeks to manifest because the substance
must be leached out of the fat. Some opc have to be activated to active
toxic state(hepatic activation of parathion to paraxon).Studies reveal that
these residues may remain for days to week even after treatment.(17)
MECHANISM OF ACTION:
Acetylcholine (ACh) is the neurotransmitter released at all
postganglionic parasympathetic nerve endings and at the synapses of both
sympathetic and parasympathetic ganglia.It is also released at the skeletal
muscle myoneural junction,and serves as a neurotransmitter in the central
nervous system.ACh is hydrolyzed by acetyl cholinesterase into two
fragments:acetic acid and choline.
Acetyl cholinesterase is present in two forms: True acetyl cholinesterase
which is found primarily in the tissues and erythrocytes,and pseudo
cholinesterase which is found in the serum and liver.
Organophosphorous compounds are acid-transferring inhibitors of
cholinesterase.They cause cholinesterase to become firmly(and sometimes
irreversibly) phosphorylated.This means that the action cholinesterase will
be inhibited.Cleavage of the carbon-enzyme bond form ACh is complete
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in a few microseconds. However,the breaking of the phosphorous-enzyme
bond requires a period varying from 60 minutes to several weeks,depending
on the organophosphorous compound involved.
Reactivation of the inhibited enzyme may occur spontaneously.The
rate of reactivation will depend on the species,the tissue,and the chemical
group attached to the enzyme.Reactivation may be enhanced by hydrolysis
of the acid-radical-enzyme through the use of oximes(i.e. reactivation
agents).Response to reactivating agent is declining with time.This process
is being caused by’’ageing’’ of the inhibited enzyme.Ageing is probably
the result  of the loss of one alkyl or alkoxy group,leaving a much more
stable acetyl cholinesterase.The aged phosphorylated enzyme cannot be
reactivated  by oximes.
Accumulation of acetylcholine causes overstimulation of both
muscarinic and nicotinic receptors,and subsequently disrupts the
transmission of nerve impulses in both the peripheral and central nervous
system.(17)
Fig 1
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Most of these OPC do not posses a positive charge;hence they react
with esteratic site but not with anionic site.Splitting of the acid group then
occurs.
The bond between phosphorous and esteratic site(free site) is more
stable than the bond between carbon atom acetyl choline and the same
site.Thus blocking of the active site and consequent inactivation of
enzymes results in accumulation of acetylcholine at cholinergic sites.Pseudo
cholinesterase  is a less  specialized enzyme as it lacks an anionic site in a
position that specially adapts it to react with acetylcholine.It does however
react with acetyl choline, albeit, more slowly and also with a wide range of
other esters.
BIOLOGICAL INTERACTIONS OF OPC (18).
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CLINICAL FEATURES
The clinical features depend upon the end points were sustained
cholinergic stimulation takes palce namely
a. Post ganglionic parasympathetic hollow end organ(muscarinic)
b. Sympathetic and parasympathetic ganglionic and somatic neuro
mucsular junction(nicotinic)
c. Central nervous system affection(19)
Following exposure to organophosphorous compounds,the toxic
features are usually obvious within 30 minutes to 3 hours.This may be
delayed in some cases depending on the rate and amount of systematic
absorption.The majority of patients give a history of intentional or accidental
ingestion of organophosphorous compunds.Toxcity is produced by the
rapid absorption of the compound through the gastrointestinal,respiratory
tracts and skin.
The clinical symptoms and signs are non-specific and will depend on
the specific agent,the quantity and the route of entry.Some patients present
with vomiting,diarrhea and abdomianl pain,whilst others may be unconscious
on arrival at the hospital.A high index of suspicion is therefore needed to
make an early diagnosis. Early cases present predominantly with
parasympathetic over-activity, and a charasteristic garlic smell.The end result
may be multi-system manifestation involving the gastrointestinal,
reapiratory,and cardovascular and nervous systems,as well as involvement
of skeletal muscle, other organs and metabolic effects such as hypo or
hyperglycemia.Most fatalities occur within 24 hours and those who recover
usually do so within 10 days.
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CARDIAC MANIFESTATIONS:
The commonest cardiac manifestations following poisoning are
hypotension (with warm,dilated peripheries),and bradycardia.Patients
seldom present with tachycardia and hypertension due to predominant
nicotinic receptor blockade.Cardiac manifestations are often the cause of
serious complications and fatality.(20).
Table3. Symptoms and signs of organophosphorous poisoning
  Muscarinic receptors Nicotinic receptors Central receptors
Cardiovascular Cardiovascular General effects
 Bradycardia  Tachycardia  Anxiety
 Hypotension  Hypotension  Restlessness
Respiratory Muscuskeletal  Ataxia
 Rhinorrhoea  Weakness  Comvulsions
 Bronchorrhoea  Fasciculation  Insomnia
 Bronchospasm  Cramps  Tremors
 Cough  Paralysis  Coma
Gastrointestinal  Absent reflexes
 Nausea/vomiting  Respiratory
 Increased depression
salivation  Circulatory
 Abdominal         collapse
cramps
 Diarrhea
 Faecal
incontinence
Geniturinary
 Urinary
continence
Eyes
 Blurred vision
 Increased
Lacrimation
 Miosis
Glands
 Excessive
salivation
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The mechanism of cardiac toxicity is unclear and the following has
been postulated:
 A direct toxic effect on the myocardium
 Over activity of cholinergic or nicotinic receptors causing
hemodynamic alteration
 Hypoxia
 Acidosis
 Electrolyte abnormalities
 High dose atropine therapy (used as treatment for organophosphate
poisoning)
RESPIRATORY MANIFESTATIONS :
Respiratory manifestations of acute organophosphorous poisoning
include bronchorrhoea,rhinorrhoea,bronchospasm and laryngeal spasm.This
is due to the action of the organophosphate on muscarinic receptors.The
intergrity of the airway may be compromised by excessive secretions.The
nicotinic effects lead to weakness and subsequent paralysis of respiratory
and oropharyngeal muscles.This increases the likehood of both airway
obstruction and aspiration of gastric contents. Finally,central neurological
depression may lead to respiratory arrest.
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GASTROINTESTINAL MANIFESTATIONS :
Symptoms resembling gastroenterities such as vomiting, diarrhea and
abdominal cramps are the first to occur after oral ingestion of an
organophosphorous compound.
NEUROLOGICAL MANIFESTATIONS :
A large number of patients, following acute exposure to
organophosphorous compounds, require prolonged ventilatory support in
the intensive care unit due to neuromuscular weakness.  The neurological
menifestations have therefore been a primary focus of interest.   There has
been  an emphasis on reducing the incidence of neuro - muscular respira-
tory failure.  Three different types of paralysis are recognized based largely
on the time of occurance and their differing pathophysiology :
 Type I Paralysis or acute paralysis
 Type II Paralysis or Intermediate Syndrome
 Thpe III Paralysis  or Organophosphate - induced delayed polyneuropathy.
ENDOCRINE CHANGES IN PESTICIDES
In critical illness, several drugs and various stressful conditions modify
the functions of neurotransmitters which consequently affect the secretion
of pituitary hormones.  Although the role of neurotransmitters in the
regulation endocrine system is well known, cholinergic actions have been
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less investigated. Organophosphoate compounds may result in sick
euthyroid syndrome. These conditions may be related to the effects of
acetylcholine and direct effect of organophosphate compounds.
Cholinesterase inhibitors were shown to modify the pituitary-thyroid and
pituitary- adrenal axes.  Pesticides such as soman have been shown to
produce a significant increase in serum corticosterone, thyroxine, and
triidothyronine concentrations after poisoning.  Thyroid function in
pregnant womem is a critical determinant of offspring’s IQ and
contaminants such as polychlorinated biphenyls and dioxins are known to
disrupt thyroid function.  Such findings demonstrate the special sensitives
of developing embryos and fetuses to chemical exposure levels that are
safe and without effect in mature adults.
OTHER EFFECTS OF OPC MAY INCLUDE
 Neuropsychiatric effects : Impaied memory, confusion, irritability, leth-
argy, psychosis and chronic organophosphate- induced Neuropsychi-
atric disorders have been repored.  The mechanism is not proven. (21)
 Extra pyramidal effects : These are characterized by dystonia, cogwheel
rigidity, and parkinsonian features (Basal ganglia impairment after
recovery from acute toxicity).
 Other neurological and / or psychological effects : Guillain - Barre-like
syndrome and isolated bilateral recurrent laryngeal nerve palsy are
possible.(22)
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 Ophthalmic effects : Optic neuropathy, retinal degeneration, defective
vertical smooth pursuit, myopia and miosis (due to direct ocular
exposure to organphosphates), are possible.
 Ears: Ototoxicity is also possible(23).
MODIFIED DREIBACH’CLINICAL CRITERIA - KARNIT (24)
GRADE I - Mild symptoms related to portal of entry.
Nausea,vomiting in case of ingestion
Cough,burning sensation in the chest in case of inhalation
Mild systematic symptoms like headache, Dizziness,
weakness
GRADE II - Moderate systematic intoxication
Abdominal pain and diarrhea in case of ingestion.
Tightness in chest,difficulty in breathing in case of
inhalation
Salivation, Lacrimation, Sweating, Pupillary changes.
Bradycardia, confusion, tremor, restlessnes.
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GRADE III - Severe systemic intoxication
Respiratory depression,generalized weakness
Cyanosis, peripheral circulatory failure,
Convulsion,coma.
DIAGNOSTIC CRITERIA(19)
 INVESTIGATORY MODALITES:ESTIMATION OF
CHOLINESTERASE LEVELS:Organophosphate (OP)
toxicity is a clinical diagnosis.Confirmation of organophosphate
poisining is based on the measurement  of cholinesterase
activity;typically,these resluts are not readily available.Altough
RBC and plasma (pseudo)cholinesterase levels can both be
used,RBC cholinesterase correlates better with CNS acetyl
cholinesterase (AChe) and is,therefore,a more useful marker of
organophosphate poisoning.
 Meauremaent of  RBC and plasma cholinesterase levels
prior to treatment  with pralidoxime (2-PAM).Monitoring
serial levels can be used to determine a response to therapy.
 RBC AChE represents the AChE found on RBC
membranes,similar to that found in neuronal
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tissue.Therefore, RBC AchE measurement more accurately
reflects nervous system OP AChE inhibition.
 Plasma cholinesterase is a liver acute-phase protein that
circulates in the blood plasma.It is found in CNS. White
matter,the pancreas,and the heart. It can be affected by
many factors, including pregnancy,infection, and
medical  illness. Additionally, a patient’s levels can  vary
up to 50% with repeated testing.
 RBC cholinesterase is the more accurate of the 2
measurements,but plasma cholinesterase is easier to assay
and is more readily available.
 Cholinesterase levels do not always correlate with severity
of clinical illness.
 The level of cholinesterase activity is relative and is based
on population estimates.Neonates and infants have
baseline levels that are lower than adults.Because most
patients do not know their baseline level ,the diagnosis can
be confirmed by observing a progressive increase in the
cholinesterase value until the value plateau over time.
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 Falsely depressed levels of erythrocyte cholinesterase can
be found in pernicious anemia,hemoglobinopathies,use of
antimalarial drugs,and oxalate blood tubes.
 Falsely depressed levels of plasma cholinesterase are
obreserved in liver dysfunction,low- protein conditions,
neoplasia,hypersenstivity reactions,use of certain drugs
(succinylcholine,codeine,and morphine), pregnancy,and
genetic deficiencies.
 Other laboratory findings include leukocytosis,
hemoconcentration, metabolic acidosis, hyperglycemia,
hypokalemia, and hypomagnesemia.
IMAGING STUDIES
A chest radiograph may reveal pulmonary edema but typically adds
little to the clinical management of a poisoned patient.  Electrocardiographic
manifestations include prolonged Q-Tc intervals, elevation of the ST
segment, inverted T waves and a prolonged PR interval.  There may also
be rhythm abnormalities such as sinus bradycardia, ventricular extra-systoles,
ventricular tachycardia and fibrillation.  Ludomirsky et al described three
phases of cardiac toxicity following organophosphate poisoning :
 Phase I : A brief period of increased symphathetic tone.
 Phase II : A prolonged period of parasympathetic activity in-
cluding AV node blockade
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 Phase III : Q-T prolongation followed by torsades de pointes,
ventricular tachycardia and ventricular fibrillation (25)
THERAPEUTIC CONSIDERATIONS
Medical Care : Airway control and adequate oxygenation are
paramount in organophosphate poisonings.  Intubations may be necessary
in cases of respiratory distress due to laryngospasm, bronchospasm,
bronchorrhoea, or seizures.  Immediate aggressive use of atropine may
eliminate the need for intubation. (26) Succinylcholine should be avoided
because it is degraded by acetyl cholinesterase (AChE) and may result in
prolonged paralysis.
 Continuous cardiac monitoring and pulse oximetry should be
established; an ECG should be performed.  Torsades de Pointes
should be treated in the standard manner.  The use of intraenous
magnesium sulfate has been reported as beneficial for
organophosphate toxicity. (27) The mechanism of action may
involve acetylcholine antagonism or ventricular membrance
stabilization.
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 Remove all clothing and gently cleanse patients suspected of
organophosphate exposure with soap and water because
organophosphates are hydrolyzed readily in aqueous solutions
with a high pH.  Consider clothing hazardous waste and discard
accordingly.
 Health care providers must avoid contaminating themselves while
handling patients. Use personal protective equipment, such as
neoprene or nitrile gloves and gowns, when decontaminating
patients because hydrocarbons can penetrate non polar
substances such as latex and vinyl.  Use charcoal catridge masks
for respiratory protection when decontaminating patients who
are significantly contaminated.
 Irrigate the eyes of patients who have ocular exposure using
isotonic saline.
 If ingestion occured within 30 to 60 minutes placement of
nasogastric tube and administration of activated charcoal in a
dose, 1g / kg orally.  Cathartics are contraindicated because of
electrolyte imbalance. (28)
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Atropine administration : 3-5mg rapid intravenous should be given to
reach effective atropinisation.  The adequate atropinisation is gauged by
five paramenters.
1. Pulse rate > 85 / min
2. Systolic blood pressure> 80mm Hg
3. Absence of lung crackles.
4. Dry axilla.
5. No constricted pupils (20)
Then after three to five minutes, if the parameters are not attained,
double the initial dosing.  Atropine should be given in doubling dose pattern
till adequate atropinisation.
Maintenance of atropinisation: 10-20% of the bolus dose should be
given as infusion in 100ml normal saline and the parameters are assessed
every 15 miniutes.  If there is inadequate atropinisation superimposed bolus
in the dosage of 3-5 mg should be given. Atropine should be tailored down
hourly for six hours and then every two to three hours for the next 24hrs.
Meticulous watch for atropine toxicity such as agitation, confusion, retention
of bladder, hyperthermia, ileus and tachycardia should be done.
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Glycopyrrolate can be used instead of atropine.  It does not raise the
heart rate (49).
OXIMES : PRALIDOXIME (2-PAM OR PROTO PAM ) (29)
Cholinesterase reactivation
Oximes are nucleophilic agents that re-activate the phosphorylated acetyl
cholinesterase by binding to the organophosphorous molecule.  The use of
oximes in acute organophosphorous poisoning has been a controversial
subject for the last two decades as there have been very few randomized
controlled trials that have addressed the role of pralidoxime (PAM).
Pralidoxime has three main actions.
 A direct reaction converting the organophosphate to a harmless
compound.
 A transient reaction protecting the enzyme from further inhibition.
 Reactivation of the inhibited alkyl phosphorylated enzyme to free the
active unit (if given early enough)
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The reactivating action of pralidoxime is most marked at the nicotinic
skeletal neuromuscular junction. It does not reverse the muscarinic
manifestations of organophosphorous poisoning.  Pralidoxime should be
started as early as possible to prevent permanent binding of the
organophosphate to acetyl cholinesterase.  Once this has occured, receptor
regeneration is required to allow recovery.  The recommended dose of
pralidoxime in organophosphorous poisoning is 500 mg/hr infusion for the
first 48 hrs. followed by 1 gm in tds for another 3 days. Pralidoxime should
be continued until adequate spontaneous ventilation is achieved by the patient.
The effective plasma concentration is 4mg / litre and the patient should
show signs of improvement 10-40 minutes after its administration. Plasma
and pseudo cholinesterase levels should ideally be monitored during
treatment.  Side effects of pralidoxime include drowsiness, visual
disturbances, nausea, tachycarida and muscle weakness, so treatment should
be reserved for potentially fatal cases.  Fresh frozen plasma can also be
used in the management of OPC (50).
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PREVENTION AND EDUCATION
Improved regulation of the availability of pesticides, strict regulation
of vendors, and modifications in packaging of pesticides may all help reduce
the  use of organophosphates as poisons.  Adequate provision of information
to the public, regular training of health care providers, better availability of
drugs/antidotes and the establishment of poison information centers will
facilitate in reducing the morbidity and mortality related to organophosphorous
poisoning. Insecticides should be kept out of reach of children, to prevent
accidental poisoning. During agricultural spraying, proper precautions should
be taken to prevent inhalation.  Accidental ingestion was reported from
Japan where there were 19,436 cases over a period of 17 years
(1953-1969). WHO used data from 19 countries and reported approximately
5,00,000 cases of pesticide poisoning annually.  Of these 99% belong to
third world countries(29). In 1981 the estimate was 75,000 cases annual and
rose to 3 million in 1983 and majority were under the age of 30 (30). Pesticide
poisoning contributes more than forty percent of cases in Poison Centre
GGH Chennai.  The mortality rate due to this poison is 42.29% (case register
2001-2004). The victims are farmers of rural South India.
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OBJECTIVES
1. To describe the epidemiology of Pesticide poisoning in poison centre,
Government General Hospital, Chennai.
2. To Study the clinical profile of Pesticide poisoning in poison Centre,
Government General Hospital, Chennai.
3. To analyze the epidemiological and clinical factors in correlation to
severity and outcome of pesticide in poison centre, Government General
Hospital, Chennai.
4. To analyse the incidence of sick Euthyroid syndrome in patients admited
with pesticide poisoning in Poison Centre Government General
Hospital, Chennai.
5. To study the correlation between the incidence of sick Euthyroid
syndrome and its assocation with out come.
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MATERIALS  AND  METHOD
SETTING :
This study was conducted in the Poison control, training and research
Centre, GGH, Chennai in collaboration of Institute of Internal Medicine
Institute of Biochemistry. It was a   prospective study done during the
period from Jan 2009 - June 2009.
INCLUSION CRITERIA :
60 Patients with history and clinical features suggestive of Pesticide
poisoning were selected irrespective of age and sex.
Ethical Clearance - obtained
Informed Concern -Obtained.
EXCLUSION CRITERIA :
1. Patient with past or present H/o. thyroid Dysfuntion
2. Patients taking drugs that will affect thyroid function
3. Patients with  liver disease
4. Patients with Renal Dysfuntion.
5. Patients with poisoning whose compound were not known.
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Patients  with known history of exposure to organophosphorous
compounds were taken into consideration. The reliability on exposure was
reinforced by definite history from the patients and their attendants. The
container from which the poison were consumed were studied for the type
and the quantity estimated.  Each patient registered for the study went through
deatiled clinical evaluation as per the proforma.  The cases were divided
into three groups as mild, moderate and severe by modified DREISBACH
criteria.  All patients underwent baseline laoratory investigations.  The gastric
aspirate was analyzed by thin layer chromatography method for the detection
of poison.
All patients underwent complete hemogram, renal function test, liver
function test, ECG, Chest roentgenogram, and thyroid function status and
serum cholrine esterase.
The other biochemical markers such as liver enzymes and amylase
were taken on day 1.
BIOCHEMICAL MARKERS AND THE METHODS EMPLOYED (KITS)
1. CHOLINESTERASE - KITNETIC COLORIMETRIC
METHOD (31)
2. SGOT (AST) - UV KINETIC METHOD (32)
28
3. SGPT - (MODIFIED IFCC METHOD) (33)
4. ALKALINE PHOSPHATASE - PNPP METHOD (34)
Ventilatory Support was considered in patients with following
parameters.
a. RR > 35/min
b. Apnea or obvious hypoventilation
c. Persistent cyanosis, excessive secretions, depressed level of
consciousness, inability to protect the air way (34)
d. PaO2 < 60mmHg, FiO2 <0.6
PaCO2 > 50mmHg, pH <7.2
Mechanical ventilation was performed with assist control mode and
SIMV either as volume or pressure control. Positive end expiratory pressure
was titrated to keep SaO2 above 94% with 40% FIO2. Weaning was
performed using either T-tube trials or pressure support weaning.  All patients
were monitored meticulously and vital signs assessed till the outcome.
Detailed evaluation of each patient was made.  Each variable in the
proforma was correlated with severity and mortality.
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RESULTS
Epidemiological Pattern of Pesticides in Poision Centre, Govt. General
Hospital
Age Distribution
Sl.No. Age Group in Years Frequency (n)
1. < 20 14 23
2. 21-30 22 37
3. 31-40 17 28
4. 41-50 6 10
5. 51-60 1 2
6. > 60
TOTAL 60 100
Percentage
Majority of Patients were in  21-30 Age Group.  The Number of Patients between the
age group 20 - 40 accounts for 65%
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GENDER
Sl.No. Sex Frequency (n)
1. Male 35 58.4
2. Female 25 41.6
TOTAL 60 100
Percentage
Male, 35, 58%
Female, 25, 42%
Male
Female
Incidence of Poisioning  was more in males when compared to females in our Series
35out of 60 are males.
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Compound Distribution
43
11
5
1
0 10 20 30 40 50
Organophosphates
Carbamate
Pyrethroid
Organochlorine
C
o
m
po
un
d
No. of cases
COMPOUND DISTRIBUTION AMONG PESTICIDES
Among the pesticides the most common compound consumed was
orgnophosphates.
Sl.No. Compound Frequency (n)
1. Organophosphates 43
2. Carbamate 11
3. Pyrethroid 5
4. Organochlorine 1
TOTAl 60
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COMPOUND DISTRIBUTION AMONG OPC
Most Common Compound among OPC was monocrotophos.
Compound Distribution among OPC
35%
14%14%
7%
7%
5%
5%
5%
2%
2%
2%
2%
Monocrotophos
Chlorphyriphos
Phosphamidon
Prophenophos +
Cypermethrin
Triasophos
Quinalphos
Chlorphyriphos +
cypermethrin
Methylparathion
Prophenophos
Ethylparathion
Dimethoate
Parathion
Nos.
Monocrotophos 16 35
Chlorphyriphos 6 14
Phosphamidon 6 14
Prophenophos + Cypermethrin 3 7
Triasophos 3 7
Quinalphos 2 5
Chlorphyriphos + cypermethrin 2 5
Methylparathion 2 5
Prophenophos 1 2
Ethylparathion 1 2
Dimethoate 1 2
Parathion 1 2
Compound Percentage
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Magnitude of Sick EuThyroid
50; 83%
10; 17%
Normal Thyroid Profile
Abnormal Thyroid Profile
MAGNITUDE  OF  SICK  EUTHYROID
Normal Thyroid 50 83
Sick Euthyroid 10 17
Thyroid Status
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Among the 60 patients studied sick Euthyroid was noted in 10 patients.
PercentageNos.
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Compound & Thyroid status
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Thyroid cases
No. of cases
COMPOUND & THYROID STATUS
Compound No. of cases Sick Euthyroid
OPC 43 10
Carbamate 11 Nil
Pyrethroid 5 Nil
Organochlorine 1 Nil
Compound & Thyroid Status
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Among the 60 paitents who were studied, sick Euthyroid status was noted
only among 10 patients with OPC Poisioning.
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OPC and Thyroid status
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Thyroid cases
No. of cases
OPC AND THYROID STATUS
Monocrotophos 16 5
Phosphamidon 6 2
Quinalphos 2 1
Methylparathion 2 1
Parathion 1 1
OPC and Thyroid status
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Thyroid cases
Among the 43 Patients with OPC Poisioning Sick Euthyroid status was
noted in 10 Patients. Maximum was among Monocrotophos poisioning.
Nos. Death
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Spectrum of Sick Euthyroid
SPECTRUM OF SICK EUTHYORID
Spectrum of Sick Euthyroid
7, 70%
3, 30%
Low T3 Alone
Low T3, T4 Low TSH
Among the 10 patients with sick Euthyroid, Low T3 alone was noted in 7
patients. 3 patients had changes in T3, T4 & TSH Levels.
Low T3 Alone 7 70
Low T3, T4 Low TSH 3 30
Spectrum No. Percentage
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Series1
ROUTE OF EXPOSURE
Ingestional exposure was more common in this series.
Sl.No. Route of Exposure Frequency (n)
1. Ingestion 59 98
2. Inhalation 1 2
TOTAL 60 100
Percentage
Mode of Poisoning
59
98%
1
2%
Ingestion
Inhalation
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CHOLINESTERASE LEVEL
19 20
4 5
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Cholinesterase Level
The Mean cholinesteras level was 1207. Among sick Eu Thyroid the mean
level was 217 which was much lower when compared to patients with no
Thyroid abnormality.
< 200 19 32
201 - 400 20 33
401 - 600 4 7
601 - 1000 5 8
> 1000 12 20
Values Nos. Percentage
THYROID N MEAN STD. DEVIATION
NEG 50 1405.0600 2118.77612
POS 10 217.6000 71.04803
TOTAL 60 1207.1500 1981.98386
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VENTILATORY  SUPPORT
32
28
26
27
28
29
30
31
32
No. of cases
Required Non required
Ventiltory Support
Ventilator was required in 53% of total Patients admitted.  All those with
sick eu thyroid were in need of ventilatory support.
Required 32 53
Non Required 28 47
Percentage
NO YES
NEG 28 22
POS 10
Thyroid Status & Ventilator
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DURATION  OF STAY IN HOSPITAL
Mean duration of stay
6, 10%
21, 35%
9, 15%
11, 18%
7, 12%
6, 10%
< 1 day
1 - 3 days
4 - 5 days
6 - 10 days
11 - 20 days
> 20 days
THY MEAN N STD. DEVIATION
NEG 4.9000 50 4.14655
POS 15.3000 10 9.84378
TOTAL 6.6333 60 6.65867
The Mean duration of stay among patients was 6.6333. Among those with
sick Eu thyroid the mean duration of stay was 15.3 which was significantly
longer than those who were negative for thyroid status.
< 1 day 6 10
1 - 3 days 21 35
4 - 5 days 9 15
6 - 10 days 11 18
11 - 20 days 7 12
> 20 days 6 10
Values Nos. Percentage
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Survival, 44
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No. of Patients
Death Survival
Outcome
Outcome 
OUTCOME
Outcome
Death, 16, 27%
Survival, 44, 73%
Among the 60 patients studied 16 of them died.  The Mortality rate was
27 %.
Death 16 27
Survival 44 73
Nos. Percentage
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COMPOUND   AND  MORTALITY
Among the 43 Patients with OPC Poisioning Maximum compound
consumed was monochrotophos and death was also maximum in the same.
Nos. Death
Monocrotophos 16 12
Chlorphyriphos 6
Phosphamidon 6 1
Prophenophos + Cypermethrin 3 1
Triasophos 3
Quinalphos 2 1
Chlorphyriphos + cypermethrin 2
Methylparathion 2 1
Prophenophos 1
Ethylparathion 1
Dimethoate 1
Parathion 1
Compound
43
64
Death Survival
outcome in sick euthyroid
OUTCOME IN SICK EUTHYROID
Death 6 60
Survival 4 40
6, 60%
4, 40%
Death
Survival
Among the 10 Patients with sick Euthyroid 6 of them expired.
The Mortality rate was 60%.
Nos. Percentage
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Spectrum of Sick Euthyroid & Mortality
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Spectrum of Sick Euthyroid & Mortality
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Among the 10 Patients with sick Euthyroid 6 of them expired. All with
changes in T3, T4 & TSH Expired (100%). Those with changes in T3
Alone had a Mortality of 42%
Nos. Death
Low T3 Alone 7 3
Low T3, T4 Low TSH 3 3
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DISCUSSION
Comprehensive analysis of 60 cases of acute organophosphorous
poisoning.
EPIDEMIOLOGY OF ORGANPHOSPHOROUS POISONING :
Age Pattern :
In this series of 60 cases,  36 cases were below the age of 30. WHO
has reported about 3 million cases of opc exposure and 40,000 detths
annually and majority were under the age group of thirty. (30) Murat Sungur
and Muhammed Guven et al of turkey observed the mean age group of opc
exposure was 30±15 years.(18) Karalliedde L, Senanayake N.et al of
SRILANKA documented 91% of their cases were under the age of 30(40).
 In Kashmir Valley Malik et al.  revealed that 33.5% of the cases of opc were
under the age of 25. (41) In Mangalore, Karnataka, India the most common
age group to be affected was 20-30 years (36.6%) (30). The series reported
in this thesis had the similar pattern of age group affection.  The reason
could be that this age group, by all probability, is vulnerable to various
emotional conflicts that occur during this phase of life.  This young age
group affected by exposure form the viable entity of any population both in
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terms of procurement and productivity.  This case study and the case reports
mentioned above throw light on the target age group for educative and
preventive programmes to reduce the incidence of opc poisoning.
SEX DISTRIBUTION
In Poison centre GGH Chennai  males were exposed more when
compared to female population.  (58.4% verses 41.6) On the contrary to
the series in Murat Sungur Study of 36 cases of opc in Turkey (18) [(female
n=25, male =22)] and. Malik et al.  Observation of 122 cases in Kashmir
valley [(female n=114, male =50)] female intoxication was more (44). In Srilanka
and Mangalore had smilar pattern to the case series of the poison centre.
(male 86%-female 14%) S. Shivakumar and K. Raghavan et al of Tamilnadu
reported 165 cases of organophosphorous poisoning and sex distribution
was similar to the case series (male n=122, female n=45) (38). This variation
was due to handling of poison by the respective sex in their respective
locality.  In kashmir the female populations are predominantly employed in
apple orchards and they are involved in pesticide control.  In southern part
of India males are actively involved in spraying fertilizers and pesticides.
ROUTE OF EXPOSURE :
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Ingestion of the OPC poisoning (n=59) formed the majoriy in this
series apart of inhalational (n=1)  form of exposure. Arup Kumar Kundu,
JD Mukhopadhyay, AK saha, S Das et al (48) studied 108 patients in sub
urban West bengal poison, 90 consumed the poison and the death rate was
12% and it had positive correlation with out come.  In Kashmir Valley out of
164 cases-ingestional route (n=140), inhalational (n=7) and topical exposure
(n=17).  In the Turkey study the gastrointestinal route was the main route in
44 (93.6%) Patients.
CLINICAL SEVERITY (MODIFIED DREISHBACH CRITERIA)
In this case series of 60 Cases admitted 49 fell into grade III and II fell
into the grade 2 group. The reason could be that this centre being a referral
unit, complicated cases, warranting specialist treatment, Intenstive care
monitoring, ventilatory support were transfered from primary helath centres,
district hospitals and private nursing homes.  Arup Kumar Kundu (et.al)
reported, mild 15 (14%), moderate 55 (50.9%) and sever 32 (29.6%) in his
study based on OPC poisoning in sub-urban West Bengal. In that study, the
severe grade of poisoning was associated with increased ventilatory support
and poor outcome.  Similarly, in this case series, clinical severity association
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with need of ventilatory support and mortality was statistically significant.
All those with sick Eu Thyroid Syndrome were in grade 3 severity and they
were in need of ventilator support.
LAB CONTRIBUTIONS
In this study group, the average total WBC court 8,686 cells cubic
mm. (SD.3433). Leukocytosis was also reported in the studies from Turkey
and pittsburg.  The liver function tests observed in this study had similar
pattern of mild elevation when compared to the study from Murat Sungurb
et al in TURKEY. Kenneth D. Ketz, et. al who documented metabolic
acidosis in his study group.
CHOLINESTERASE LEVELS AND ITS SIGNIFICANCE
In this case study, day 1 ChE correlated very well with clinical criteria
of Dreisbach.  This finding was also observed by Bobba R, Venkataraman,
BV, Pais P, Joseph T. et.al. in Bangalore.  In contrary to this observation,
S.N. Chugh and Navneeth Agarwal, et.al found no relationship between
serum CHE estimation and severity grading.  Sequential post exposure
estimations of the ChEs up to 3 days revealed significant rise in the values
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correlated with substantial clinical improvement.  This observation was in
par with the study in Bangalore. The Cholinesterase level among those with
sick euthyroid was significantly severe than those who were negative.
TREATMENT CONTRIBUTES
In this series, all patients were administrered atropine according to the
clinical severity.
In this series, 2PAM was given to all patients, 2PAM was administered
at a dose of 500 mg/hr infusion for the first 48 hrs.followed by 1 g IV tds
for another 3 days.  Arun Kumar kundu, et.al in a study in sub-urban,  West
Bengal related high dose 2PAM administered in first 24 hours was associated
with  adverse outcome (48). In 1991, De Silva studied the treatment of
organophosphate poisoning with atropine and 2PAM and, later the same
year, with atropine alone.  He found that atropine seemed to be as effective
as atropine plus 2-PAM in the treatment of acute organophosphate poisoning.
The controversy continued when other authors observed more respiratory
complications and higher mortality rates with use of high-dose 2-PAM.
Studies are underway to assess the role of low-dose 2-PAM (42) S. Shivakumar
and K. Raghavan, et. al compated the effectiveness of high dose 2PAM
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with low dose by slection of patients in non-random manner.  They found
out the high dose 2PAM group had better survival, lesser incidence of type
2 paralysis and shortened duration of ventilation.
VENTILATORY SUPPORT
Out of 60 Patients 32 needed ventilatory support.  (53%) All patients
were initiated on assist contorl mode.  16 out of 32 cases on mechanical
ventilation expired.  The morality rate among patients on mechanical
ventilation was 50%.
Grade 3 clinical severity, proximal muscle affection, low values of day
1 serum ChE were the predictors for the need of mechanical ventilation.
Murat Sungur and Muhammed Guven of Turkey in the study of 47 patients
of OPC reported mechanical ventilatory support was needed for 10 (21.2%)
patients.  The duration of mechanical ventilation was 4.1 ± 3.2 days.  The
mortality rate for the patients who were mechanically ventilated was 50%
(5 patients), although the mortality rate was 27.6% (13 patients) for all
patients.  The mortality rate for the mechanically ventilated patients was not
statistically different compared with those patients not mechanically
ventilated.  Two patients who are mechanically ventilated died with sudden
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cardio respiratory arrest following ventricular tachycardia, and three died
from pneumonia and complicating adult respiratory distress syndrome S.
Shivakumar and K. Raghavan, et.al. in their  case series of 165 patients, 22
patients were mechanically ventilated,out of which 14 died.
INCIDENCE OF SICK EUTHYROID:
Among 60 patients studied,incidence of sick euthyroid was noted in
ten patients[17%].Among those with organophosphorous compound
poisoning incidence of sick euthyoid was 23%.in study by Guven et al in
Turkey out of 22 patients with OPC poisoning sick euthyroid was noted in
7 patients[31.8%]. The Repeat thyroid profile done in 9/10 patients was
normal.
COMPOUND AND THYROID STATUS:
Among those with organophosphates the highest incidence was noted
among Monocrotophos[50%].the remaining cases were seen among patients
with phosphomindon,quinalphos ,methylparathion and parathion.
SPECTRUM OF THYROID STATUS:
In this series of 10 patients of sick euthyoid ,7 had low free T3 alone
and 3 had low T3,T4 and TSH.
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In the study by Guven et al in Turkey the spectrum of changes observed
- 2 had low fT3,2 had fT4 and 3 had low TSH.
OUTCOME ANALYSIS
In this series 16 expired.  The mortality rate was 27%.  In all cases
primary cause of death was respiratory failure with secondary cardiac arrest.
It has resulted from central respiratory depression, respiratory muscle
weakness, increased bronchial secretions, bronchospasm and acute
pulmonary oedema.  The prolonged duration of hospital stay, grade 3 clinical
serverities, proximal muscle involvement and mechanical ventilation were
associated with poor outcome.  Karalliedde L, Senanayake N. et.al. reported
mortality rate of 18% in their study of 92 cases of OPC in Sri Lanka.  Arup
Kumar Kundu, JD Mukhopadhyay, AK Saha, S Das Burdwan Medical
College and Hospital, Burdwan, West Bengal analyzed that increased time
interval before initial atropinisation, higher clinical grading, respiratory
paralysis at the time of admission, higher quantity of poison consumed,
type of poison (e.g., monocrotophos and dimethoate), poison ingested
rather than inhaled, development of encephalopathy and  or ECG changes
(pulse rate < 45/min, complete heart block QT - Prolongation), and higher
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dosage of PAM used in first 24 hours were associated with increased
mortaility.  In Kahsmire valley a study of 164 patients of OPC Poisoning,
the mortality rate was 5.5% In the Mangalore sutdy, the mortality was 26.2
%.  Murat Sungur and Muhammed Guven of Turkey reported the mortality
rate of 32%.
Among patients with sick euthyoid status [10],6 of them expired and
4 of them survived hence mortality among the patients with sick euthyroid
is higher. p<0.01. Which is statistically significant.
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SUMMARY
Organophosphorous poisoning is a menace to the human race both as
a weapon of mass destruction and a misused pesticide of self harm. The
case fatality rate exceeds 60% in developing countries where there are many
pit falls in treatment protocol and research activities.  So a comprehensive
analysis of 60 patients of organophosphorous poisoning was done in Poison
Centre, Government General Hospital Chennai.
All the cases included in the studied underwent detailed clinical
evaluation, extensive laboratory work up and thyroid function status.; Each
patient was monitored periodically till the outcome.  There were 35 meals
and 25 female patients.  The predominant age group was 21-30 years.;  59
patients were suicide attempts and one had accidential exposure.;  59 of the
patients were poisoned through the gastrointestinal route.  One patient had
inhalational poisoning.  There were 9 different types of OP insecticide agents
involved. According to Dreisbach clinical criteria at admission 49 patients
belong to the severe grade of poisoning. Serum cholinesterase levels had
significant correlation with clinical severity, mechanical ventilation and
outcome.
Thyroid Status was assesed for 60 patients.  10 Patients are changes
suggestive of sick euthyroid.  6 out of the 10 patients expired.  Those who
had changes in all three values of thyroid harmone (T3, T4, TSH) had
increased mortality
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CONCLUSION
1. Pesticide poisoning is more prevalent in the 21 - 30 age group.incidence
is more common in males.
2. The most important cause for consumption of organophosphorous
poison is self harm.
3. The commonest route of exposure is ingestion of poison and it is
associated with increased clinical severity.
4. The duration of stay in the hospital has significant correlation with
clinical severity.
5. The higher the clinical grade of poisoning at the inital presentation
more the need of ventilatory support and advers outcome.
6. The following parameters predict the need of ventilatory support,grade
3 clinical severity ,proximal mucle weakness,low values of day 1
cholinesterase.
7. The prevalence of sick euthyroid syndrome among individuals with
acute pesticide poisoning was 16.5%.
8. Death was high in those with sick euthyroid syndrome.
9. Sick euthyroid syndrome probably reflect the status of toxic effects
and /or the susceptible individuals.
10. Probable mechanisms for sick euthyroid syndrome is similar to sick
euthyroid syndrome in other critical care illnesses.
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RECOMMENDATIONS
To avoid accidental exposure while spraying pesticides,proper
precautions should be taken to prevent inhalational and accidental ingestion
of the substance.
Insecticedes should be kept out of reach of children,to prevent
accidental poisoning.
Improved regulation of the availablity of pesticides,strict regulation of
vendors,and modification in packaging of  pesticides may all help redcuce
the use of organophosphates as poisons.
Adequate provision of information to the public creates awareness
about the deleterious effects of OPCs.
Establishment of poison information centres will facilitate in  reducing
the morbidity and mortality relateed to organophosphorous poisoning.
Many countries like USA, European union ,Thailand banned the
production and sales of highly toxic OPCs like Monocrotophos.in Srilanka
severe restrictions are enforced over the utilization of Monocrotophos.
So the government on India should take necessary steps to restrict the free
availablity of highly toxic OPCs like monocrotophos.
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